TherapeuticsMD (TXMD) Capital Expenditures (2011 - 2023)

TherapeuticsMD's Capital Expenditures history runs 13 years deep, the most recent figure standing at $2.3 million for Q4 2023.

• Quarterly Capital Expenditures fell 69.65% year-over-year to $2.3 million in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.1 million (down 85.25% YoY) and the FY2023 annual result came in at $1.1 million, down 85.25% from the prior year.
• Capital Expenditures was $2.3 million for Q4 2023 at TherapeuticsMD, up from -$721000.0 in the prior quarter.
• Across five years, Capital Expenditures topped out at $7.6 million in Q4 2022 and bottomed at -$721000.0 in Q3 2023.
• A 5-year average of $636277.8 and a median of $41500.0 in 2021 frame the typical range for Capital Expenditures.
• Annual changes were most pronounced in 2019 — Capital Expenditures surged 4745.24% — and 2023, when it plunged 2200.0%.
• TherapeuticsMD's Capital Expenditures stood at $360587.0 in 2019, then plunged by 53.41% to $168000.0 in 2020, then slumped by 141.67% to -$70000.0 in 2021, then jumped by 10978.57% to $7.6 million in 2022, then slumped by 69.65% to $2.3 million in 2023.
• Business Quant data shows TXMD's Capital Expenditures at $2.3 million in Q4 2023, -$721000.0 in Q3 2023, and -$483000.0 in Q2 2023.